Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07262372 · ClinicalTrials.gov registry record · NA
Supervision in Substance Use Disorder Treatment Programs
A NA study of Substance Use Disorders and Self Efficacy, sponsored by University of Arkansas.
- Recruiting
- Registry status
- NA
- Development phase
- 43
- Enrollment target
- 1
- Study location
NCT07262372: Recruiting NA study of Substance Use Disorders and Self Efficacy, sponsored by University of Arkansas.
NCT07262372 is a NA study of Substance Use Disorders and Self Efficacy that is actively recruiting participants, run by University of Arkansas. The registered enrollment target is 43 participants, below the 500-participant average among 93 other Substance Use Disorders trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07262372, a NA study of Substance Use Disorders and Self Efficacy, is actively recruiting participants, sponsored by University of Arkansas.
- RECRUITING
- Registry status
- NA
- Development phase
- 43 participants
- Enrollment target
- 1
- Study location
Study Summary
Substance use disorders such as opioid addiction affect millions of adults in the United States each year, but the delivery of high-quality, effective addiction services is disrupted by organizational issues such as counselor burnout and turnover. Clinical supervisors are essential for supporting counselors in specialty addiction treatment programs, but few supervisors receive supervision-focused training. This project seeks to develop and pilot an evidence-based supervision strategy that has a high potential to enhance supervision and result in improved counselors' well-being and performance and, in turn, to improve client outcomes.
Primary Outcome
Self-reported survey response at the counselor level (Efficacy subscale on TCU ORC; 1-5 Likert scale, higher scores are better; Lehman WEK, Greener JM, Simpson DD. Assessing organizational readiness for change. J Subst Abuse Treat. 2002;22(4):197-209. doi: 10.1016/S0740-5472(02)00233-7.)
Conditions Studied
Interventions
- OTHER FOCUS supervision strategy
Study Locations (1)
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2025-07-21 |
| Est. Completion | 2027-06-30 |
| Phase | NA |
What NCT07262372 shows while recruiting
NCT07262372 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 500-participant average among 93 other Substance Use Disorders trials with a reported enrollment target (91% lower).
The record links to 4 conditions, with Substance Use Disorders appearing as the primary indexed condition, and to 1 intervention - of which FOCUS supervision strategy is the first listed.
NCT07262372 reports a single indexed study location in Arkansas.
Frequently Asked Questions
What is clinical trial NCT07262372 about?
NCT07262372 is a clinical study titled "Supervision in Substance Use Disorder Treatment Programs". Substance use disorders such as opioid addiction affect millions of adults in the United States each year, but the delivery of high-quality, effective addiction services is disrupted by organizational issues such as counselor burnout and turnover. Clinical supervisors are essential for supporting co...
What is the current status of trial NCT07262372?
This trial is currently recruiting. It is a NA study. The enrollment target is 43 participants. The study started on 2025-07-21. Estimated completion is 2027-06-30.
What conditions does trial NCT07262372 study?
This clinical trial studies the following conditions: Substance Use Disorders, Self Efficacy, Burnout, Professional, Supervision.
What interventions are being tested in trial NCT07262372?
The interventions under investigation include: FOCUS supervision strategy (OTHER).
Who is sponsoring clinical trial NCT07262372?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07262372 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Substance Use Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07262372's enrollment target sits among peer trials
43 74th of 93 higher than 20 of 93 other Substance Use Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Substance Use Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Supporting Treatment Access and Recovery Through Linkage and Support
RECRUITING · NA
-
Development OF A Novel Peer Recovery Supporter Training Platform
RECRUITING · NA
-
Project I Test: Implementing HIV Testing in Opioid Treatment Programs
RECRUITING · NA
-
Testing Strategies to Improve Substance Misuse Prevention Research Use in State Policy Contexts
RECRUITING · NA
-
Families Left Behind
RECRUITING · NA
-
Trauma Screening/Referral and Interpersonal Violence Prevention for Women with Substance Use Disorders
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI